Fujirebio has a long history establishing novel, high-quality antibodies for development of immunoassays for in vitro diagnostic (IVD) use.
The company uses both established hybridoma technology as well as recombinant DNA techniques in combination with screening and selections strategies to identify the most useful binders.
Antibody pairs binding the target antigen in solution with high affinity are identified with label-free biosensor technology. Fujirebio has established an array of technologies, including phage-display based methods, for epitope mapping and identification of the exact amino acid sequence involved in the antibody/antigen binding.
Detailed knowledge of the binding epitopes enables not only empirical testing of the binding specificity of each antibody, but also in-silico cross-reactivity testing towards protein sequence databases of potential interference.
The antibody isotype, isoelectric point, thermal stability, and hydrophobicity are other intrinsic factors considered when selecting the best antibody candidates.